Unknown PHASE1 INTERVENTIONAL 1-arm NCT04174898

MSC Infusion for Anti-aging and Regenerative Therapy (REGEN)

Human Mesenchymal Stem Cell (hMSC) Infusion for Anti-Aging and REGENerative Therapy

Sponsor: CytoMed Therapeutics Pte Ltd

Conditions Aging Well Regenerative Medicine

Interventions human Mesenchymal Stem Cell (MSC) infusion therapy

Updated 5 times since 2019 Last updated: Nov 20, 2019 Started: Apr 15, 2020 Primary completion: Apr 14, 2021 Completion: Apr 14, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04174898, this PHASE1 trial focuses on Aging Well and Regenerative Medicine and remains ongoing. Sponsored by CytoMed Therapeutics Pte Ltd, it has been updated 5 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
May 2022 — Jul 2024 [monthly]

Unknown Status PHASE1

Status: Not Yet Recruiting → Unknown Status
Jan 2021 — May 2022 [monthly]

Not Yet Recruiting PHASE1
Dec 2019 — Jan 2021 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CytoMed Therapeutics Pte Ltd
Landmark Medical Centre Sdn Bhd

Data source: Landmark Medical Centre Sdn Bhd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Johor Bahru, Malaysia